Impact of Gender on Cardiovascular Outcome in Patients at Cardiovascular High Risk: Analysis of the Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)
نویسندگان
چکیده
Ctr for Cardiovascular Research, Inst of Pharmacology, Charité – Univ Medicine Berlin, Berlin; Klinik für Innere Medizin III, Univ Clinic of the Saarland, Homburg/Saar; Dept of Nephrology and Hypertension, Univ of Erlangen-Nürnberg, Erlangen; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; Population Health Research Inst, McMaster Univ, Hamilton, Canada; CV Medicine, John Radcliffe Hosp, Oxford, United Kingdom
منابع مشابه
Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown cardioprotective and renoprotective properties. These agents are recommended as first-line therapy for the treatment of hypertension and the reduction of cardiovascular risk. Early studies pointed to the cardioprotective and renoprotective effects of ARBs in high-risk patients. The ONgoing Telmi...
متن کاملEffects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
BACKGROUND Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown. METHODS AND RESULTS In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE...
متن کاملIn a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events
BACKGROUND AND OBJECTIVES Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/day) in reducing cardiovascular events. Clinicians in Asia doubt tolerability of these doses for their patients. We therefore analyzed data from this study and a p...
متن کاملErectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
BACKGROUND Although erectile dysfunction (ED) is associated with cardiovascular risk factors and atherosclerosis, it is not known whether the presence of ED is predictive of future events in individuals with cardiovascular disease. We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces ...
متن کاملHealth Services and Outcomes Research Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients
Jennie Johnstone, MD; Mark Loeb, MD, MSc; Koon K. Teo, MBBCh, PhD; Peggy Gao, MSc; Leanne Dyal, MSc; Lisheng Liu, MD; Alvaro Avezum, MD, PhD; Ernesto Cardona-Munoz, MD; Peter Sleight, MD; Robert Fagard, MD, PhD; Salim Yusuf, MD, DPhil; on behalf of the Ongoing Telmisartan Alone and in Combination With Ramipril Global EndPoint Trial (ONTARGET) and Telmisartan Randomized Assessment Study in ACE I...
متن کامل